PMID- 15686110
OWN - NLM
STAT- MEDLINE
DCOM- 20050302
LR  - 20221207
IS  - 1078-0297 (Print)
IS  - 1078-0297 (Linking)
VI  - 113-114
DP  - 2003
TI  - The risk of atherosclerosis in patients with impaired glucose tolerance.
PG  - 87-95
AB  - OBJECTIVES: Glucose metabolism disorders usually coexist with dyslipidemia and 
      coagulation/fibrinolysis disturbances. Increase of insulin resistance followed by 
      hyperinsulinemia leads to enhanced protein synthesis, including production of 
      apolipoproteins. As a result, the structure of Low Density Lipoprotein (LDL) 
      becomes small and dense. This augments lipid infiltration into the arterial wall. 
      Following this process monocyte adhesion to endothelium initiates atherosclerotic 
      injury. One of the markers of this inflammatory reaction is Monocyte 
      Chemoattractant Peptide-1 (MCP-1). A lot of inflammatory mediators affect both 
      oxidative modification of LDL and coagulation processes being responsible for 
      anti-fibrinolytic predominance. Plasminogen Activator Inhibitor-1 (PAI-1) is a 
      marker of this state. Therefore the aim of this study is to evaluate the marker 
      of the oxidation processes (oxLDL) as well as prothrombotic (PAI-1) and 
      inflammatory state (MCP-1) markers in patients with Impaired Glucose Tolerance 
      (IGT). METHODS: The study was carried out on 16 subjects: 10 with biochemically 
      confirmed IGT and 6 age-matched healthy persons without such disorders. Following 
      tests were performed: OGTT, HbA(1c) level as well as TCh, HDL, LDL and TG. Plasma 
      concentrations of oxLDL, PAI-1 and MCP-1 were measured using ELISA method. 
      RESULTS: In patients with Impaired Glucose Tolerance plasma levels of oxLDL were 
      significantly higher compared to control group (67.6 +/- 0.9 U/l vs. 57.8 +/- 4.0 
      U/l; p < 0.01) in spite of LDL levels, which did not reveal such difference. 
      MCP-1 plasma concentration compared to control group occurred to be significantly 
      increased in experimental group as well (156.4 +/- 9.2 ng/ml vs. 125.4 +/- 1.9 
      ng/ml; p < 0.05). PAI-1 level revealed most significant difference (84.0 +/- 1.8 
      ng/ml vs. 43.7 +/- 2.7 ng/ml; p < 0.0001). CONCLUSIONS: It is concluded that 
      patients with Impaired Glucose Tolerance should be considered as a group in which 
      atherogenic modification of lipoproteins occurred. Also plasma inflammatory as 
      well as prothrombotic markers concentration was elevated.
FAU - Okopien, B
AU  - Okopien B
AD  - Department of Clinical Pharmacology, Medical University of Silesia, Medykow 18, 
      40-752 Katowice, Poland. mbkdokop@mp.pl
FAU - Stachura-Kulach, A
AU  - Stachura-Kulach A
FAU - Kulach, A
AU  - Kulach A
FAU - Kowalski, J
AU  - Kowalski J
FAU - Zielinski, M
AU  - Zielinski M
FAU - Wisniewska-Wanat, M
AU  - Wisniewska-Wanat M
FAU - Sierant, M
AU  - Sierant M
FAU - Kalina, Z
AU  - Kalina Z
FAU - Herman, Z Stanislaw
AU  - Herman ZS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Mol Pathol Pharmacol
JT  - Research communications in molecular pathology and pharmacology
JID - 9437512
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Monocyte Chemoattractant Proteins)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (oxidized low density lipoprotein)
SB  - IM
MH  - Adult
MH  - Arteriosclerosis/etiology
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Glucose Metabolism Disorders/*blood/complications
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Lipoproteins, LDL/*blood
MH  - Middle Aged
MH  - Monocyte Chemoattractant Proteins/*blood
MH  - Plasminogen Activator Inhibitor 1/*blood
MH  - Risk Factors
EDAT- 2005/02/03 09:00
MHDA- 2005/03/03 09:00
CRDT- 2005/02/03 09:00
PHST- 2005/02/03 09:00 [pubmed]
PHST- 2005/03/03 09:00 [medline]
PHST- 2005/02/03 09:00 [entrez]
PST - ppublish
SO  - Res Commun Mol Pathol Pharmacol. 2003;113-114:87-95.